[{"orgOrder":0,"company":"PureTech Health","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"PureTech Advances LYT-100 for Treatment of Serious Respiratory Complications that Persist Following Resolution of COVID-19 Infection","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2020","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical"},{"orgOrder":0,"company":"PureTech Health","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"PureTech Initiates Phase 2 trial of LYT-100 (Deupirfenidone) in Long COVID Respiratory Complications and Related Sequelae","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Phase II","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"December 2020","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II"},{"orgOrder":0,"company":"PureTech Health","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"PureTech Initiates Phase 2a trial of LYT-100 (Deupirfenidone) in Lymphedema","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase II","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"December 2020","url1":"","url2":"","graph1":"Immunology","graph2":"Phase II"},{"orgOrder":0,"company":"PureTech Health","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"PureTech Presents Phase 1 Data for LYT-100 at the European Respiratory Society International Congress 2021","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Phase II","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"August 2021","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II"},{"orgOrder":0,"company":"PureTech Health","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"PureTech Presents Additional Phase 1 Data for LYT-100 at American Thoracic Society 2022","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Phase II","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2022","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II"},{"orgOrder":0,"company":"PureTech Health","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"PureTech Reports Results from Phase 2 Study of LYT-100-COV in Post-Acute \u201cLong\u201d COVID with Respiratory Complications","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2022","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II"},{"orgOrder":0,"company":"PureTech Health","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"PureTech Initiates Late-Stage Study of LYT-100 in IPF and Advances LYT-200","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Phase II","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2022","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II"},{"orgOrder":0,"company":"PureTech Health","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"PureTech Presents Data for LYT-100 (Deupirfenidone) Supporting Design of Dose-Ranging Trial in Idiopathic Pulmonary Fibrosis (IPF) at European Respiratory Society International Congress 2022","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Phase II","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2022","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II"},{"orgOrder":0,"company":"PureTech Health","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"PureTech Announces Completion of Enrollment in Phase 2b ELEVATE IPF Trial of LYT-100 (Deupirfenidone) in Idiopathic Pulmonary Fibrosis","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Phase II","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2024","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II"}]
Find Clinical Drug Pipeline Developments & Deals for Deupirfenidone
LYT-100 (deupirfenidone) is an inhibitor of IL-6 and TNF alpha. It is being evaluated for the treatment of patients with idiopathic pulmonary fibrosis.
LYT-100 (deupirfenidone) was well-tolerated compared to pirfenidone in a healthy older adult crossover trial, informing dose selection for recently initiated trial in IPF.
IPF study will evaluate efficacy of two doses of LYT-100 (deupirfenidone), one with comparable exposure to FDA-approved dose of pirfenidone and one with higher exposure, vs. placebo, as well as relative tolerability and efficacy vs. pirfenidone.
No treatment effect observed in this patient population for LYT-100-COV (deupirfenidone) substantial improvement in 6-minute walk test seen in both placebo and active groups.
Further data from Phase 1 study in healthy older adults demonstrate improved tolerability profile of LYT-100 (deupirfenidone), a deuterated form of pirfenidone, an approved anti-inflammatory and anti-fibrotic drug, compared to pirfenidone.
A dose-proportional PK profile was observed with LYT-100 throughout the range of doses studied. In the single ascending food effect cohort, exposure was slightly lower in the fed condition.
Study will further evaluate safety and tolerability of LYT-100 and explore clinical efficacy endpoints in paƟents with breast-cancer related, upper limb secondary lymphedema.
LYT-100 is a deuterated, oral small molecule designed to overcome the challenges associated with pirfenidone, an approved and marketed anti-inflammatory and anti-fibrotic drug. Phase 2 trial will evaluate LYT-100 in Long COVID respiratory complications and related sequelae.
The global, randomized, placebo-controlled trial is expected to begin in Q3 2020 and will evaluate LYT-100 in non-critical COVID-19 patients with respiratory complications.
Market Place
Upload your Marketing & Sales content on your company Virtual Booth, click HERE
